We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-4 of 4

FDA to speed up inspection and warning process
  • Gowling WLG
  • USA
  • August 21 2009

On August 6, 2009, the USFDA's top official Margaret Hamburg vowed to speed up the reporting of warnings related to problems found during inspections and to act more aggressively in serious cases that could harm consumers and patients.

Apotex alleges it is injured by Ranbaxy's ability to launch on schedule
  • Gowling WLG
  • USA
  • July 27 2009

In two different cases before the US District Court for the Middle District of North Carolina Apotex has alleged that Ranbaxy's inability to launch its generic versions of donepezil hydrochloride (sold by Eisai Co. under the brand Aricept) and valacyclovir hydrochloride (sold by GSK under the brand Valtrex) on time will injure Apotex.

Isabel Raasch
  • Gowling WLG